However, systemic changes in some interleukin (IL-2, IL-5, and IL-6) levels determined in the same cohort of ALS patients might indicate specific adaptive immune system responses depending on the current disease stage. This evidence concerns the gene IL2 and amyotrophic lateral sclerosis.